Appointments

Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

  • SIDTALKSScience, Innovation, and Discovery at Dana-Farber

    Updates from our researchers for our Joint Visiting Committee Symposium

    Kimberly Stegmaier, MD
    Advances in Pediatric Cancer Research

    Did you know that cancer is still the leading cause of death by disease in children? Learn more about pediatric cancer research from Kimberly Stegmaier, MD, co-director of Dana-Farber/Boston Children's pediatric Hematologic Malignancy Program, in her SIDTALK on research to discover new drug targets and develop new treatments for pediatric patients.

     
    About Kimberly Stegmaier, MD

    Kimberly Stegmaier, MD, is an associate professor of Pediatrics at Harvard Medical School, a principal investigator in Pediatric Oncology at Dana-Farber Cancer Institute, and an attending physician at Dana-Farber/Boston Children's. She is co-director of the pediatric Hematologic Malignancy Center at Dana-Farber/Boston Children's, and is also an associate member of the Broad Institute of Harvard and MIT. She received her BS from Duke University and her MD from Harvard Medical School. Dr. Stegmaier completed her residency at Boston Children's and a post-doctoral pediatric hematology-oncology fellowship at Dana-Farber/Boston Children's.

    Kimberly Stegmaier, MD - large  

    Dr. Stegmaier focuses on genomic approaches to drug discovery. Her laboratory integrates chemical biology, genomic, and proteomic approaches to discover new lead compounds and protein targets for cancer therapy. She has trained her efforts on the two pediatric acute leukemias (AML and ALL) and the two pediatric solid tumors of childhood, Ewing sarcoma and neuroblastoma.

    With the Broad Institute, Dr. Stegmaier developed a new method of chemical discovery called gene expression-based high-throughput screening (GE-HTS). This technique led to the discovery of chemicals that induce the maturation of acute myeloid leukemia (AML) cells, and resulted in a clinical trial for patients with relapsed AML. Many malignancies are believed to arise from the abnormal proliferation of cells and the failure of primitive cells to differentiate. For this reason, Dr. Stegmaier studies the differentiation defect in two model diseases, AML and neuroblastoma.

    Related resources

    Normal enzyme aids a mutant one to fuel blood cancer's growth
    Genomics: Identifying Drug Candidates through Gene Expression Screening
    Genetic biomarker may help identify neuroblastomas vulnerable to novel class of drugs
    Pediatric Resource Program — assisting patients and families in need 

  •   Email
  •   Print
  •   Share
  • Personalized Medicine Research

    • Barrett Rollins, MD, PhD and Neil Lindeman, MDLearn about Profile, a comprehensive somatic genotyping study that focuses on the development of targeted treatments for every person with cancer.
  • Support Cancer Research

    • To learn more about the many ways you can support Dana-Farber’s research initiatives with a philanthropic gift, please contact Rebecca Freedman at 617-632-4215 or rebecca_freedman@
      dfci.harvard.edu
      .
    • Give Now